COMPOUND, PHARMACEUTICAL COMPOSITION, PACKAGED PHARMACEUTICAL COMPOSITION, METHOD OF TREATING A PATIENT WHO HAS A DISEASE RESPONSIBLE FOR BTK ACTIVITY, METHOD OF TREATING A PATIENT WHO HAS A CLEAR ALTERNATIVE DISEASE, CUSTOMS DISEASE INCREASING SENSITIVITY OF CANCER CELLS TO CHEMOTHERAPY, METHOD OF REDUCING MEDICATION ERROR AND IMPROVING THERAPEUTIC PATIENT DISEASE BY BEING TREATED TO A DISEASE RESPONSIBLE FOR BTK MÉTIR DE MÉDID ACTIVITY INHIBITION BTK IN A SAMPLE, METHOD OF INHIBITING B-CELL ACTIVITY
PETER A. BLOMGREN,KEVIN S. CURRIE,JEFFREY E. KROPF,SEUNG H. LEE,JAMES W. DARROW,SCOTT A. MITCHELL,JIANJUN XU,AARON C. SCHMITT
申请号：
BRPI0716918
公开号：
BRPI0716918A2
申请日:
2007.09.11
申请国别(地区):
BR
年份:
2013
代理人:
摘要：
At least one chemical entity chosen from compounds of Formula 1 and pharmaceutically acceptable salts, solvates, chelates, non-covalent complexes, prodrugs, and mixtures thereof is described herein. Pharmaceutical compositions comprising at least one chemical entity of the invention, together with at least one pharmaceutically acceptable vehicle chosen from carriers adjuvants, and excipients, are described. Methods of treating patients suffering from certain diseases responsive to inhibition of Btk activity and/or B-cell activity are described. Methods for determining the presence of Btk in a sample are described.
